Praxis Precision Medicines, Inc. PRAX Vormatrigine — Program-specific expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses?
- Praxis Precision Medicines, Inc. (PRAX) reported vormatrigine — program-specific expenses of $20.49M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses changed year-over-year?
- Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses increased by 49.2% year-over-year, from $13.73M to $20.49M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses has grown at a 243.5% compound annual growth rate (CAGR), from $6.28M to $74.06M.
- What does vormatrigine — program-specific expenses mean?
- This metric represents the direct costs associated with the development, production, and commercialization activities for the Vormatrigine therapeutic program. It captures the specific financial resources allocated to clinical trials, manufacturing, and supply chain operations dedicated to this asset. Monitoring these expenses provides insight into the capital intensity and operational progress of the company's key pipeline candidates.